ASCO 2024 | PATRICIA: Phase II study of palbociclib, trastuzumab, and endocrine therapy in HER2+ advanced BC

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, presents the primary efficacy analysis of the randomized cohort C from the PATRICIA trial (NCT02448420). This Phase II study evaluated the efficacy of palbociclib combined with trastuzumab (and endocrine therapy in patients with HER2-positive, hormone receptor-positive (HR+/HER2+), PAM50 luminal advanced breast cancer. This randomized, open-label, phase II study recruited patients from August 2019 to August 2023 across 34 sites in Spain. Eligible patients had received at least one prior anti-HER2 regimen and were stratified by previous regimens and presence of visceral disease. Among 73 randomized patients, the palbociclib cohort demonstrated significantly longer progression-free survival (PFS) compared to treatment of physicians’ choice. Grade ≥3 adverse events, mainly neutropenia, were more common in the palbociclib cohort. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.